journal article·2021-08-26Open access

Natural Dietary and Medicinal Plants with Anti-Obesity Therapeutics Activities for Treatment and Prevention of Obesity during Lock Down and in Post-COVID-19 Era

Wenli Sun, Mohamad Hesam Shahrajabian, Qi Cheng

Applied Sciences· Volume 11· Issue 17

Abstract

Overweight and obesity have become global epidemics, especially during the lockdown due to the COVID-19 pandemic. The potential of medicinal plants as a better and safe option in treating obesity and overweight has gained attention in recent years. Obesity and overweight has become a major public health concern, and its incidence rising at an alarming rate. Obesity is one of the major types of metabolic syndrome, resulting in various types of problems such as hypertension, diabetes, dyslipidemia, and excess fat accumulation. The current searching was done by the keywords in main indexing systems including Scopus, PubMed/MEDLINE, the search engine of Google Scholar, and Institute for Scientific Web of Science. The keywords were traditional medicine, health benefits, pharmaceutical science, pomegranate, punicalin, punicalagin, and ellagitannins. Google Scholar was searched manually for possible missing manuscripts, and there was no language restriction in the search. This review was carried out to highlight the importance of medicinal plants which are common in traditional medicinal sciences of different countries, especially Asia to prevent and treatment of obesity and overweight during the global pandemic and the post-COVID-19 era.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pharmacology and Obesity Treatment · Psidium guajava Extracts and Applications · Mangiferin and Mango Extracts

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China

State Key Laboratory of North China Crop Improvement and Regulation, Hebei Agricultural University, Baoding 071000, China

Global Alliance of HeBAU-CLS&HeQiS for BioAl-Manufacturing, College of Life Sciences, Hebei Agricultural University, Baoding 071000, China

Funding

the Natural Science Foundation of Beijing, China · National Key R&D Program of China

References (100+)

Show source-provided references
1. Exploring Artemisia annua L., artemisinin and its derivatives, from traditional Chinese wonder medicinal science10.15835/nbha48412002 ↗
2. Chemical components and pharmacological benefits of basil (Ocimum basilicum): A review10.1080/10942912.2020.1828456 ↗
3. Traditional herbal medicine for the prevention and treatment of cold and flu in the autumn of 2020, overlapped with COVID-19
4. Traditional herbal medicines to overcome stress, anxiety and improve mental health in outbreaks of human coronaviruses
5. Chinese herbal medicine for SARS and SARS-CoV-2 treatment and prevention, encouraging using herbal medicine for COVID-19 outbreak
6. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases from SARS to SARS-CoV-210.1080/21645515.2020.1797369 ↗
7. Plant species used in Brazil and Asia regions toxic properties
8. Asafoetida, a natural medicine for a future10.2174/1573401317666210222161609 ↗
9. Improving health benefits with considering traditional and modern health benefits of Peganum harmala10.1186/s40816-021-00255-7 ↗
10. Shahrajabian, M.H., Sun, W., and Cheng, Q. (2021). Different methods for molecular and rapid detection of human novel coronavirus. Curr. Pharm. Des.10.2174/1381612827666210604114411 ↗
11. Obesity and cardiovascular disease: The Hippocrates paradox?10.1016/S0735-1097(03)00784-8 ↗
12. Obesity and cardiovascular disease pathophysiology, evaluation, and effect on weight loss10.1161/01.ATV.0000216787.85457.f3 ↗
13. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity10.1038/nri1937 ↗
14. Wlodarczyk, M., and Slizewska, K. (2021). Obesity as the 21st century’s major disease: The role of probiotics and prebiotics in prevention and treatment. Food Biosci., 42.10.1016/j.fbio.2021.101115 ↗
15. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects10.1016/j.dsx.2020.04.033 ↗
16. Brown, A., Flint, S.W., Kalea, A.Z., O’Kane, M., Williams, S., and Batterham, R.L. (2021). Negative impact of the first COVID-19 lockdown upon health-related behaviours and psychological wellbeing in people living with severe and complex obesity in the UK. EClinicalMedicine, 34.10.1016/j.eclinm.2021.100796 ↗
17. Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data10.1016/j.metabol.2020.154345 ↗
18. Obesity during the COVID-19 pandemic: Both cause of high risk and potential effect of lockdown? A population-based electronic health record study10.1016/j.puhe.2020.12.003 ↗
19. Tobore, T.O. (2020). Towards a comprehensive theory of obesity and a healthy diet: The causal role of oxidative stress in food addiction and obesity. Behav. Brain Res., 384.10.1016/j.bbr.2020.112560 ↗
20. Combination of obesity and co-morbidities leads to unfavorable outcomes in COVID-19 patients10.1016/j.sjbs.2020.11.081 ↗
21. Higher body mass index is an important risk factor in COVID-19 patients: A systematic review and meta-analysis10.1007/s11356-020-10132-4 ↗
22. Association of obesity with illness severity in hospitalized patients with COVID-19: A retrospective cohort study10.1016/j.orcp.2021.02.006 ↗
23. Cai, H., Yang, L., Lu, Y., Zhang, S., Ye, C., Zhang, X., Yu, G., Gu, J., Lian, J., and Hao, S. (2021). High body mass index is a significant risk factor for the progression and prognosis of imported COVID-19: A multicenter, retrospective cohort study. BMC Infect. Dis., 21.10.1186/s12879-021-05818-0 ↗
24. Du, Y., Lv, Y., Zha, W., Zhou, N., and Hong, X. (2021). Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis. Metabolism, 117.10.1016/j.metabol.2020.154373 ↗
25. Natural anti-obesity agents and their therapeutic role in management of obesity: A future trend perspective10.1016/j.biopha.2018.11.076 ↗
26. Functional foods-dietary or herbal products on obesity: Application of selected bioactive compounds to target lipid metabolism10.1016/j.cofs.2020.09.011 ↗
27. Do flavanols-rich natural products relieve obesity-related insulin resistance?10.1016/j.fct.2017.12.055 ↗
28. Identification of PPAR-activating compounds in herbal and edible plants and fungi from Vietnam10.1016/j.indcrop.2018.12.003 ↗
29. An update on pharmacotherapeutic strategies for obesity10.1080/14656566.2021.1888927 ↗
30. Obesity in women-a life cycle of medical risk
31. Obesity vaccines10.4161/hv.27537 ↗
32. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk10.1080/21623945.2017.1402151 ↗
33. Overweight and obesity among under-five children in South Asia10.1080/2574254X.2020.1769992 ↗
34. Phentermine and topiramate extended-release: A new treatment for obesity and its role in a complications-centric approach to obesity medical management10.1517/14740338.2013.806481 ↗
35. Worldwide trends in childhood overweight and obesity10.1080/17477160600586747 ↗
36. Healthy obesity as an intermediate state of risk: A critical review10.1080/17446651.2016.1220298 ↗
37. Effect of obesity on the outcome of pneumonia10.1080/17446651.2017.1368387 ↗
38. The global childhood obesity epidemic and the association between socio-economic status and childhood obesity10.3109/09540261.2012.688195 ↗
39. Prevalence and healthcare costs of obesity-related comorbidities: Evidence from an electronic medical records system in the United States10.3111/13696998.2015.1067623 ↗
40. Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing10.1080/17477160600586689 ↗
41. Canadian childhood obesity estimates based on WHO, IOTF and CDC cut-points10.3109/17477160903268282 ↗
42. Female obesity: Short-and long-term consequences on the offspring10.3109/09513590.2013.777420 ↗
43. Urinary markers of nucleic acid oxidation in Danish overweight/obese children and youths10.3109/10715762.2016.1164310 ↗
44. Strategies for prevention and treatment of obesity among children in Taiwan10.1080/15438620903413230 ↗
45. Estimated burden of paediatric obesity and co-morbidities in Europe. Part 2. Numbers of children with indicators of obesity-related disease10.1080/17477160600586689 ↗
46. Family in pediatric obesity management: A literature review10.1080/17477160801896994 ↗
47. Obesity in patients with HIV infection: Epidemiology, consequences and treatment options10.1080/17446651.2016.1220297 ↗
48. Hospital rehabilitation for patients with obesity: A scoping review10.1080/09638288.2016.1243163 ↗
49. Independent and synergistic associations of asthma and obesity with systemic inflammation in adolescents10.3109/02770903.2012.728271 ↗
50. Effects of obstructive sleep apnea and gastroesophageal reflux disease on asthma control in obesity10.3109/02770903.2011.601778 ↗
51. The effects of being overweight and obese on female reproduction: A review10.3109/09513590.2013.850660 ↗
52. Why some obese people become depressed whilst others do not: Exploring links between cognitive reactivity, depression and obesity10.1080/13548506.2018.1524153 ↗
53. Sleep duration, asthma and obesity10.3109/02770903.2013.831871 ↗
54. Association between obesity and periodontal risk indicators in adolescents10.3109/17477166.2010.495779 ↗
55. Dark and light side of obesity: Mortality of metabolically healthy obese people10.1586/eem.12.58 ↗
56. Abbas, A.M., Fathy, S.K., Fawzy, A.T., Salem, A.S., and Shawky, M.S. (2020). The mutual effects of COVID-19 and obesity. Obes. Med., 19.10.1016/j.obmed.2020.100250 ↗
57. The role of obesity in inflammatory markers in COVID-19 patients10.1016/j.orcp.2020.12.004 ↗
58. Coping strategies for obese individuals with obstructive sleep apnea during COVID-19 pandemic: A narrative review10.1016/j.obmed.2021.100324 ↗
59. Ghanemi, A., Yoshioka, M., and St-Amand, J. (2020). Will an obesity pandemic replace the coronavirus disease-2019 (COVID-19) pandemic?. Med. Hypotheses, 144.10.1016/j.mehy.2020.110042 ↗
60. Potential pathophysiology of COVID-19 in patients with obesity10.1016/j.bja.2020.05.055 ↗
61. Pontiroli, A., Sala, L.L., Chiumello, D., and Folli, F. (2020). Is blood glucose or obesity responsible for the bad prognosis of COVID-19 in obesity-diabetes?. Diabetes Res. Clin. Pract., 167.10.1016/j.diabres.2020.108342 ↗
62. Obesity and outcomes in COVID-19: When an epidemic and pandemic collide10.1016/j.mayocp.2020.05.006 ↗
63. Mulugeta, W., and Hoque, L. (2021). Impact of the COVID-19 lockdown on weight status and associated factors for obesity among children in Massachusetts. Obes. Med., 22.10.1016/j.obmed.2021.100325 ↗
64. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis10.1016/j.dsx.2020.09.029 ↗
65. Belancic, A., Kresovic, A., and Racki, V. (2020). Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Obes. Med., 19.10.1016/j.obmed.2020.100259 ↗
66. The obesity paradox: Analysis from the Smatteo COVID-19 Registry (SMACORE) cohort10.1016/j.numecd.2020.07.047 ↗
67. Huang, Y., Lu, Y., Huang, Y.-M., Wang, M., Ling, W., Sui, Y., and Zhao, H.-L. (2020). Obesity in patients with COVID-19: A systematic review and meta-analysis. Metabolism, 113.10.1016/j.metabol.2020.154378 ↗
68. SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity10.1016/j.dsx.2020.07.030 ↗
69. Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates?10.1016/j.soard.2020.04.038 ↗
70. Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico10.1016/j.arcmed.2020.12.002 ↗
71. Beck, A.L., Huang, J.C., Lendzion, L., Fernandez, A., and Martinez, S. (2021). Impact of the COVID-19 pandemic on parents’ perception of health behaviors in children with overweight and obesity. Acad. Pediatr.
72. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review10.1016/j.dsx.2020.05.020 ↗
73. Leija-Martinez, J.J., Huang, F., Del-Rio-Navarro, B.E., Sanchez-Munoz, F., Munoz-Hernandez, O., Giacoman-Martinez, A., Hall-Mondragon, M.S., and Espinosa-Velazquez, D. (2020). IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19. Med. Hypotheses, 144.10.1016/j.mehy.2020.109935 ↗
74. Tsenoli, M., Smith, J.E.M., and Khan, M.A.B. (2021). A community perspective of COVID-19 and obesity in children: Causes and consequences. Obes. Med., 22.10.1016/j.obmed.2021.100327 ↗
75. Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity10.1016/j.numecd.2020.07.040 ↗
76. Rahmati-Ahmadabad, S., and Hosseini, F. (2020). Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity. Obes. Med., 19.10.1016/j.obmed.2020.100245 ↗
77. When pandemics collide: The impact of COVID-19 on childhood obesity10.1016/j.pedn.2020.11.004 ↗
78. Halvatsiotis, P., Kotanidou, A., Tzannis, K., Jahaj, E., Magira, E., Theodorakopoulou, M., Konstandopoulou, G., Gkeka, E., Pourzitaki, C., and Kapravelos, N. (2020). Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. Diabetes Res. Clin. Pract., 166.10.1016/j.diabres.2020.108331 ↗
79. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding10.1016/j.orcp.2020.05.009 ↗
80. High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification10.1016/j.biochi.2020.07.001 ↗
81. Robinson, E., Boyland, E., Chisholm, A., Harrold, J., Maloney, N.G., Marty, L., Mead, B.R., Noonan, R., and Hardman, C.A. (2021). Obesity, eating behavior and physical activity during COVID-19 lockdown: A study of UK adults. Appetite, 156.10.1016/j.appet.2020.104853 ↗
82. Obesity could shift severe COVID-19 disease to younger ages10.1016/S0140-6736(20)31024-2 ↗
83. Chowdhury, A.I., Alam, M.R., Rabbi, M.F., Rahman, T., and Reza, S. (2021). Does higher body mass index increase COVID-19 severity? A systematic review and meta-analysis. Obes. Med., 23.10.1016/j.obmed.2021.100340 ↗
84. The effect of body mass index on outcomes among COVID-19 patients with left ventricular assist devices: A multi-institutional study10.1016/j.healun.2021.01.331 ↗
85. Do, M.H., Lee, H.-B., Oh, M.-J., Jhun, H., Choi, S.Y., and Park, H.-Y. (2021). Polysaccharide fraction from greens of Raphanus sativus alleviates high fat diet-induced obesity. Food Chem., 343.10.1016/j.foodchem.2020.128395 ↗
86. Pietri, L., Giorgi, R., Begu, A., Lojou, M., Koubi, M., Cauchois, R., Grangeot, R., Dubois, N., Kaplanski, G., and Valero, R. (2021). Excess body weight is an independent risk factor for severe forms of COVID-19. Metabolism, 117.10.1016/j.metabol.2021.154703 ↗
87. Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis10.1016/j.diabet.2020.07.005 ↗
88. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: A prospective, community-based cohort study
89. Impact of obesity and diabetes mellitus in critically ill patients with SARS-CoV-210.1016/j.orcp.2021.05.001 ↗
90. Association of plant-based dietary patterns with psychological profile and obesity in Iranian women10.1016/j.clnu.2019.07.019 ↗
91. Tsigalou, C., Paraschaki, A., Karvelas, A., Kantartzi, K., Gagali, K., Tsairidis, D., and Bezirtzoglou, E. (2021). Gut microbiome and Mediterranean diet in the context of obesity. Current knowledge, perspectives and potential therapeutic targets. Metabol. Open, 9.10.1016/j.metop.2021.100081 ↗
92. Adherence to a health plant diet may reduce inflammatory factors in obese and overweight women-a cross-sectional study10.1016/j.dsx.2019.07.019 ↗
93. Rajan, L., Palaniswamy, D., and Mohankumar, S.K. (2020). Targeting obesity with plant-derived pancreatic lipase inhibitors: A comprehensive review. Pharmacol. Res., 155.10.1016/j.phrs.2020.104681 ↗
94. Shimoda, Y., Okada, J., Yamada, E., Okada, K., Okada, S., and Yamada, M. (2020). Association between percentage of obese people and water hardness in water purification plants. Obes. Med., 19.10.1016/j.obmed.2020.100244 ↗
95. Jupp, P.W. (2020). Selected environmental factors in a complex systems approach to managing obesity. Obes. Med., 19.10.1016/j.obmed.2020.100275 ↗
96. Sun, N.-N., Wu, T.-W., and Chau, C.-F. (2016). Natural dietary and herbal products in anti-obesity treatment. Molecules, 21.10.3390/molecules21101351 ↗
97. Anti-obesity effect of Triticum aestivum sprout extract in high-fat-diet-induced obese mice10.1080/09168451.2015.1006567 ↗
98. AbdelMassih, A., Ye, J., Kamel, A., Mishriky, F., Ismail, H.-A., Ragab, H.A., El Qadi, L., Malak, L., Abdu, M., and El-Husseiny, M. (2020). A multicenter consensus: A role of furin in the endothelial tropism in obese patients with COVID-19 infection. Obes. Med., 19.10.1016/j.obmed.2020.100281 ↗
99. Managing obesity through natural polyphenols: A review10.1016/j.fufo.2020.100002 ↗
100. Potential use in the treatment of inflammatory disorders and obesity of selected wild edible plants from Calabria region (Southern Italy)10.1016/j.sajb.2019.11.029 ↗